Contract Pharma: Stephen McQuaker on HPAPI Manufacturing Trends
Contract Pharma's latest article entitled 'HPAPI Manufacturing Trends' features Quotient Sciences' Director of Drug Development Consulting, Stephen McQuaker discussing the development of early-stage new chemical entity (NCE) drug candidates.
This latest article refers to a rising demand for oncology drugs in the market, advancements in manufacturing technology, and a rise in capacity to meet greater demand and drive market growth. Indeed, in just the past 5 years alone, Quotient Sciences' scientific experts have successfully worked on over 300 oncology drug development projects across multiple disease indications.
Read more of Stephen's recent contribution on Contract Pharma's website by following the link below.